| Project/Area Number |
15K10192
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Nagoya City University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
松尾 洋一 名古屋市立大学, 大学院医学研究科, 准教授 (40381800)
森本 守 名古屋市立大学, 大学院医学研究科, 助教 (60722569)
佐藤 崇文 名古屋市立大学, 大学院医学研究科, 研究員 (10747257)
齊藤 健太 名古屋市立大学, 大学院医学研究科, 助教 (10770240)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Keywords | 膵癌 / ゲムシタビン耐性 / CXCR4 / CXCR4 antagonist / 新規膵癌治療薬 / CXCL12 |
|---|
| Outline of Final Research Achievements |
Gemcitabine (Gem) is widely used for chemotherapy for pancreatic cancer, but the effect is not fully satisfactory, and the reason is resistance. We succeeded in establishing a Gem-resistant pancreatic cancer cell line and confirmed that the expression of CXCR4, a cancer stem cell marker, is enhanced along with resistance with DNA microarray. We also found that CXCR4 is involved in the proliferation and infiltration of Gem-resistant pancreatic cancer via cancer stromal interaction, which was confirmed to be suppressed by control of CXCR4 signal such as CXCR4 antagonist. Based on the above findings, we found a new finding that control of CXCR4 is a target for novel therapeutic drugs in Gem-resistant pancreatic cancer.
|
